Monographie - Hydrochlorothiazide - Stabilis 4.0

Pēdējā atjaunošana :
08/05/2024

Diurētiķis

Hydrochlorothiazide

Orāls šķīdums

Stabilitāte farmaceitisko preparātu

Maisījuma stabilitāte

Stabilitāti ietekmējoši faktori

Saderība

Literatūras saraksts

Pdf

Ķīmiskā uzbūve

Orāls šķīdums

Literatūras saraksts

Orāls šķīdums

Literatūras saraksts : Hydrochlorothiazide

	Tips	Publicēšana
2435	Žurnāls	Allen LV, Jr, Erickson MA, Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids Am J Health-Syst Pharm 1996 ; 53: 2304-2309.
3361	Žurnāls	Santovena A, Hernandez-Paiz Z, Farina J.B. Design of a pediatric oral formulation with a low proportion of hydrochlorothiazide. Int J Pharm 2012 ; 423: 360-364.
3399	Plakāts	Li Y.Y, Postma D.J, Wagenaar H.W.G. Development of a hydrochlorothiazide 0.5 mg/mL oral solution for children. EAHP Congress Paris 2013
3910	Žurnāls	Polonini H.C, Silva S .L, de Almeida T.R, Brand?o M.A, Ferreira A.O. Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions. EJHP 2016 ; 23: 352-358.
4177	Žurnāls	Polonini H, Loures da Silva S, Fernandes Brandao M.A, Bauters T, De Moerloose B, De Oliveira Ferreira A. Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF PH4. Int J Pharm Compound 2018 ;22,6:516-526
4198	Žurnāls	Uriel M, Gomez-Rincon C, Marro D. Stability of regularly prescribed oral liquids formulated with SyrSpend® SF. Pharmazie 2018 73;196-201
4256	Žurnāls	Binson G, Beuzit K, Migeot V, Marco L, Troussier B, Venisse N, Dupuis A. Preparation and Physicochemical Stability of Liquid Oral Dosage Forms Free of Potentially Harmful Excipient Designed for Pediatric Patients. Pharmaceutics 2019 ;11,190:

Mentions Légales